Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$17.75 +0.5%	$18.83	$13.53 ▼ $35.25	$1.78B	2.35	1.44 million shs	1.43 million shs
CRSP CRISPR Therapeutics	$39.25 +1.5%	$37.34	$30.04 ▼ $67.88	$3.39B	1.88	1.68 million shs	1.97 million shs
NTLA Intellia Therapeutics	$9.67 +6.7%	$7.98	$5.90 ▼ $28.18	$1.00B	2.33	2.54 million shs	5.21 million shs
VRTX Vertex Pharmaceuticals	$447.18 +1.5%	$480.76	$377.85 ▼ $519.88	$114.83B	0.51	1.41 million shs	1.51 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+0.51%	-1.66%	+4.41%	-48.03%	-28.54%
CRSP CRISPR Therapeutics	+1.47%	+5.45%	+3.92%	-25.97%	-29.24%
NTLA Intellia Therapeutics	+6.73%	+16.23%	+33.75%	-21.25%	-62.65%
VRTX Vertex Pharmaceuticals	+1.48%	+3.51%	-8.57%	-5.21%	+0.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	3.3079 of 5 stars	4.5	1.0	0.0	3.5	2.5	0.6
CRSP CRISPR Therapeutics	3.0944 of 5 stars	4.3	1.0	0.0	2.6	3.3	0.6
NTLA Intellia Therapeutics	4.6743 of 5 stars	4.3	1.0	4.7	3.8	2.5	1.3
VRTX Vertex Pharmaceuticals	4.6624 of 5 stars	3.3	5.0	3.3	4.2	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$48.75	174.65% Upside
CRSP CRISPR Therapeutics	2.50	Moderate Buy	$71.75	82.80% Upside
NTLA Intellia Therapeutics	2.67	Moderate Buy	$36.90	281.59% Upside
VRTX Vertex Pharmaceuticals	2.59	Moderate Buy	$515.04	15.18% Upside

Current Analyst Ratings Breakdown

Latest CRSP, VRTX, NTLA, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00 ➝ $81.00
5/20/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00 ➝ $65.00
5/20/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/19/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00 ➝ $10.00
5/12/2025	NTLA Intellia Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $45.00
5/9/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $42.00
5/9/2025	NTLA Intellia Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $10.00
5/9/2025	NTLA Intellia Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$68.00 ➝ $68.00
5/8/2025	CRSP CRISPR Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$53.00 ➝ $47.00
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00

(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.58M	28.07	N/A	N/A	$12.04 per share	1.47
CRSP CRISPR Therapeutics	$35M	96.85	N/A	N/A	$22.52 per share	1.74
NTLA Intellia Therapeutics	$45.57M	21.98	N/A	N/A	$11.73 per share	0.82
VRTX Vertex Pharmaceuticals	$11.10B	10.35	N/A	N/A	$63.90 per share	7.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$132.53M	-$4.61	N/A	N/A	N/A	-41.07%	-16.22%	-10.94%	8/5/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-981.54%	-18.46%	-15.79%	8/4/2025 (Estimated)
NTLA Intellia Therapeutics	-$481.19M	-$5.23	N/A	N/A	N/A	N/A	-49.34%	-40.27%	N/A
VRTX Vertex Pharmaceuticals	-$535.60M	-$3.92	N/A	25.54	2.11	-4.86%	-2.02%	-1.49%	8/7/2025 (Estimated)

Latest CRSP, VRTX, NTLA, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A
5/5/2025	Q1 2025	VRTX Vertex Pharmaceuticals	$4.29	$4.06	-$0.23	$2.49	$2.85 billion	$2.77 billion
2/25/2025	Q4 2024	BEAM Beam Therapeutics	-$1.25	-$1.09	+$0.16	-$1.09	$16.47 million	$30.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	5.07%	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	5.69	5.69
CRSP CRISPR Therapeutics	N/A	22.07	22.07
NTLA Intellia Therapeutics	N/A	6.73	6.73
VRTX Vertex Pharmaceuticals	0.01	2.69	2.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CRSP CRISPR Therapeutics	69.20%
NTLA Intellia Therapeutics	88.77%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	4.20%
CRSP CRISPR Therapeutics	4.30%
NTLA Intellia Therapeutics	3.10%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	100.56 million	79.33 million	Optionable
CRSP CRISPR Therapeutics	473	86.36 million	82.26 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	98.59 million	Optionable
VRTX Vertex Pharmaceuticals	4,800	256.80 million	256.28 million	Optionable

CRSP, VRTX, NTLA, and BEAM Headlines

Recent News About These Companies

Tema Etfs LLC Takes $4.42 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 20 at 6:16 AM | marketbeat.com

Toronto Dominion Bank Has $43.42 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 20 at 6:15 AM | marketbeat.com

Snowden Capital Advisors LLC Has $1.91 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 20 at 5:58 AM | marketbeat.com

Insider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Sells 52 Shares of Stock

May 20 at 5:18 AM | insidertrades.com

VRTX Q1 Earnings Call: New Product Launches and Pipeline Progress Amid Revenue Miss

May 20 at 3:45 AM | msn.com

Vertex Pharmaceuticals: Strategic Positioning and Promising Growth Prospects Underpin Buy Rating

May 19 at 7:24 AM | tipranks.com

Royal Bank of Canada Decreases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 19 at 6:13 AM | marketbeat.com

Quantinno Capital Management LP Has $9.70 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 18 at 5:49 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Man Group plc

May 18 at 5:28 AM | marketbeat.com

Polar Asset Management Partners Inc. Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 17, 2025 | marketbeat.com

ProShare Advisors LLC Increases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 17, 2025 | marketbeat.com

Pathstone Holdings LLC Lowers Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 17, 2025 | marketbeat.com

NorthRock Partners LLC Acquires 1,020 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 17, 2025 | marketbeat.com

Nuveen Asset Management LLC Buys 261,891 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 17, 2025 | marketbeat.com

3,802 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by Mufg Securities Americas Inc.

May 16, 2025 | marketbeat.com

Malaga Cove Capital LLC Buys Shares of 1,989 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 16, 2025 | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Nia Impact Advisors LLC

May 16, 2025 | marketbeat.com

Nissay Asset Management Corp Japan ADV Increases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 16, 2025 | marketbeat.com

1 Large-Cap Stock to Target This Week and 2 to Question

May 16, 2025 | finance.yahoo.com

OMERS ADMINISTRATION Corp Sells 1,213 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 16, 2025 | marketbeat.com

Vertex to Participate in Upcoming Investor Conferences

May 15, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
NVIDIA Stock Surges on Bullish News: How High Could It Climb?
By Thomas Hughes | May 13, 2025
View NVIDIA Stock Surges on Bullish News: How High Could It Climb?
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise
By Chris Markoch | May 16, 2025
View CRSPR Stock Could Be Ready to Deliver on Its Massive Promise

CRSP, VRTX, NTLA, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$17.75 +0.09 (+0.51%)

As of 05/20/2025 04:00 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$39.25 +0.57 (+1.47%)

As of 05/20/2025 04:00 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Intellia Therapeutics NASDAQ:NTLA

$9.67 +0.61 (+6.73%)

As of 05/20/2025 04:00 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Vertex Pharmaceuticals NASDAQ:VRTX

$447.18 +6.52 (+1.48%)

As of 05/20/2025 04:00 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time